Wegovy for Women Over 65: Activity, Muscle, and Staying Strong While Losing Weight

What Wegovy Actually Does in a Woman Over 65

Wegovy works. A woman in her late sixties or seventies who is living with obesity can expect to lose roughly 15% of her body weight on the full 2.4 mg dose, based on data from the STEP 1 trial, which enrolled adults with a BMI of 30 or higher and showed a mean weight reduction of 14.9% versus 2.4% with placebo over 68 weeks. The cardiovascular SELECT trial, with a mean participant age of 61 and a large proportion of postmenopausal women, confirmed a 20% reduction in major adverse cardiovascular events in people with established cardiovascular disease, overweight, and no diabetes.

That is a genuinely meaningful benefit for older women, who carry disproportionate cardiovascular risk after menopause.

The problem is what else comes off alongside the fat.

The Muscle Loss Problem Is Bigger After 60

Women lose muscle mass at an accelerated rate after menopause, a process called sarcopenia. Estrogen loss directly impairs muscle protein synthesis, meaning your body is already struggling to hold on to lean tissue before Wegovy enters the picture. Research in Obesity Reviews confirms that GLP-1 receptor agonists produce weight loss that is proportionally higher in lean mass than diet-alone interventions in older adults, with up to 39% of total weight shed coming from muscle and bone-associated tissue rather than fat.

For a 180-pound woman who loses 27 pounds on Wegovy, that could mean roughly 10 pounds of that loss is lean mass. Ten pounds of muscle is the difference between rising easily from a chair and needing help. It affects grip strength, gait speed, and balance.

Gait Speed as a Survival Marker

Gait speed is not a minor detail. In women over 65, a gait speed below 0.8 meters per second is associated with significantly higher mortality risk, according to a pooled analysis published in JAMA. Rapid weight loss that strips muscle can slow your walking pace. Any treatment plan that ignores this is incomplete.

How Postmenopausal Physiology Changes the Drug's Risk Profile

Bone Density Is Already Under Pressure

Estrogen is the primary hormonal protector of bone. After menopause, bone mineral density drops at roughly 1 to 2% per year in the early postmenopausal years and continues declining more slowly thereafter. Caloric restriction accelerates bone resorption. GLP-1 receptors are expressed in osteoblasts, and there is some preclinical evidence that semaglutide may have modest direct bone-protective effects, but human trial data remain limited and mixed. Do not assume the drug protects your bones. The evidence is not there yet in women specifically.

Women 65 and older should have baseline DEXA scanning before or shortly after starting Wegovy, following USPSTF osteoporosis screening guidelines, which recommend screening for all women 65 and older regardless of risk factors.

Orthostatic Hypotension and Fall Risk

Semaglutide causes nausea, vomiting, and appetite suppression. These reduce fluid and calorie intake. In a woman over 65 who is already on antihypertensive medication, the combined effect can produce orthostatic hypotension: a drop in blood pressure when standing that causes dizziness or lightheadedness. The FDA prescribing information for Wegovy does not specifically quantify fall risk in older adults because geriatric-specific trial data are sparse, but clinical caution about this interaction is warranted and well-supported by general geriatric medicine evidence.

Falls are not a minor complication in this age group. One in four women over 65 falls each year, and hip fractures carry a one-year mortality rate of up to 30% in older adults.

Cognitive and Mental Health Considerations

Emerging data suggest GLP-1 receptors in the brain may influence mood and cognition. This is an active research area. Anecdotally, some women report improved mental clarity with weight loss. The STEP 5 trial at 104 weeks did not identify cognitive harm signals, but the trial was not powered to detect them in older adults specifically. Discuss any new memory concerns, mood changes, or depressive symptoms with your prescriber. Depression in older women is often underdiagnosed and may worsen with appetite suppression and social isolation from nausea.

Activity Considerations: What to Do, What to Avoid, and Why It Matters More at 65

Physical activity is the most effective available tool for preserving lean mass during GLP-1-induced weight loss. This is not optional for women in this life stage. It is what separates successful aging from accelerated functional decline.

Resistance Training Is the Priority

The American College of Sports Medicine recommends that adults over 65 perform resistance training at least two days per week, targeting all major muscle groups. For women on Wegovy, this floor should be considered a minimum, not a target.

Effective approaches include:

• Bodyweight exercises (squats, modified push-ups, step-ups) performed at home
• Machine-based gym training, which reduces joint injury risk compared to free weights for beginners
• Resistance band programs, which are particularly appropriate if joint pain or balance concerns limit conventional weight training
• Water resistance training, which provides muscle load with minimal fall and joint-stress risk

You do not need a gym membership. You need progressive overload. That means gradually increasing the difficulty of the exercise over weeks, whether by adding repetitions, resistance, or both.

Protein Intake by Meal

Older women have anabolic resistance, meaning your muscles respond less efficiently to protein compared to a 35-year-old. To drive the same amount of muscle protein synthesis, you need more protein per meal, not just more protein per day spread thinly.

The practical target is 25 to 30 grams of high-quality protein per meal, based on research showing that this dose saturates the leucine-mediated mTOR signaling that triggers muscle repair. Wegovy suppresses appetite, which makes hitting this target difficult. Many women on semaglutide find they cannot face a full meal. Protein shakes, Greek yogurt, eggs, cottage cheese, and fish are compact, protein-dense options that require less volume to reach the threshold.

A registered dietitian with experience in older women and GLP-1 therapy is the right person to help you structure this. WomanRx's clinical team can connect you with one.

Aerobic Exercise and Cardiovascular Benefit

Walking is the most accessible aerobic activity and directly addresses the cardiovascular risk that makes Wegovy a meaningful drug in this age group. The SELECT trial's cardiovascular benefit was seen in a population with established cardiovascular disease, and physical activity compounds that benefit.

Target at least 150 minutes of moderate-intensity aerobic activity per week, per American Heart Association guidelines. For older women with limited mobility, accumulating activity in 10-minute bouts throughout the day is equally effective for cardiovascular benefit compared to single longer sessions, per research in JAMA Internal Medicine.

Balance Training to Reduce Fall Risk

Given that Wegovy may cause dizziness and orthostatic symptoms, explicit balance training should be part of the activity plan. Options include:

• Tai chi: a Cochrane review of 108 trials found it reduces falls in community-dwelling older adults
• Single-leg standing exercises, progressing to eyes-closed as balance improves
• Heel-to-toe walking
• Standing from a seated position without using hands (sit-to-stand), which builds hip and quadriceps strength simultaneously

What to Limit or Approach Carefully

High-impact activities with significant fall risk deserve caution during the early titration period when nausea and dizziness are most pronounced. This does not mean avoiding them permanently. It means being strategic about timing: do demanding activities when you are least likely to be dizzy (typically not immediately after your weekly injection, when peak plasma concentrations occur around 24 to 48 hours post-dose).

Swimming, cycling, and rowing are lower fall-risk aerobic options during titration.

Dose, Titration, and What the Geriatric Evidence Actually Shows

The standard Wegovy titration schedule starts at 0.25 mg weekly and increases every four weeks to the maintenance dose of 2.4 mg. This schedule was designed for the general adult population. The FDA label does not require dose modification for age alone, but older women frequently need extended titration time because gastrointestinal side effects are less well-tolerated and dehydration risk is higher.

A practical framework for women 65+ that WomanRx clinicians apply:

| Titration Phase | Standard Duration | Older Women: Consider Extending If | |---|---|---| | 0.25 mg | 4 weeks | Nausea causes >10% meal reduction | | 0.5 mg | 4 weeks | Dizziness on standing or vomiting >2x/week | | 1.0 mg | 4 weeks | Ongoing significant nausea or weight loss exceeding 1 lb/week | | 1.7 mg | 4 weeks | Similar to above; reassess baseline BP and hydration | | 2.4 mg | Maintenance | Not all older women need or tolerate the full dose |

Staying at 1.7 mg rather than pushing to 2.4 mg is a clinically defensible choice if side effects are burdensome. Weight loss at 1.7 mg in STEP 1 was approximately 12.4%, meaningfully less than 14.9% at 2.4 mg but still substantial and likely sufficient for cardiovascular benefit.

"School": Health Literacy, Chronic Disease Management, and Self-Monitoring at 65+

The term "school" in the context of Wegovy for older adults refers to the structured education component that optimizes outcomes. It is not about a classroom. It covers what you monitor, what you track, and what you report.

What to Monitor Yourself

• Weekly weight, same time and conditions
• Blood pressure, especially in the first 12 weeks: standing after sitting for 5 minutes, to catch orthostatic drops
• Protein intake by meal: a simple notebook or phone app works
• Exercise log: note resistance training sessions and balance practice
• Bowel habits: constipation is the most common GI side effect in older adults on semaglutide, per STEP trial pooled data, and unmanaged constipation worsens abdominal discomfort

What Your Prescriber Should Review

At every check-in (typically monthly during titration, quarterly at maintenance):

• Muscle function: grip strength if available, ability to rise from a chair without arms, self-reported gait difficulty
• Medications requiring dose adjustment with weight loss: antihypertensives, insulin, sulfonylureas
• Thyroid function: hypothyroidism is more prevalent in women over 60 and can blunt weight loss response to semaglutide; TSH should be checked annually
• Kidney function: semaglutide is not dose-adjusted for renal impairment in current labeling, but older women with chronic kidney disease need monitoring for dehydration-related acute kidney injury during periods of nausea and vomiting

The Polypharmacy Consideration

Women 65 and older take a median of five prescription medications. Semaglutide slows gastric emptying, which delays the absorption of orally administered drugs including levothyroxine, oral contraceptives (less relevant in this age group), bisphosphonates, and some blood pressure medications. Take levothyroxine 30 to 60 minutes before your first food or liquid of the day, as standard guidance recommends, and flag any medication timing changes with your pharmacist.

Pregnancy, Lactation, and Contraception

Wegovy is contraindicated in pregnancy. The FDA label carries this contraindication based on animal studies showing fetal harm at doses producing exposures below those seen in humans at therapeutic doses. Rodent and rabbit studies showed reduced fetal weight, structural abnormalities, and increased early pregnancy loss.

For women 65 and older, spontaneous pregnancy is not a practical concern given the certainty of postmenopause in this age group. However, a woman who has not had a menstrual period for fewer than 12 consecutive months, regardless of age, has not yet met the clinical definition of menopause and retains theoretical fertility. If any ambiguity exists about menopausal status, an FSH level above 40 mIU/mL on two occasions alongside amenorrhea confirms menopause.

Lactation is not relevant in this age group. No breastfeeding data exist for semaglutide, and the drug would not be prescribed during lactation regardless of age.

No contraception discussion is required for fully postmenopausal women. For the rare perimenopausal woman in her early 60s who is still within 12 months of her last period, contraception until confirmed menopause remains advisable.

Who This Is Right For and Who Should Think Carefully

Women Over 65 Most Likely to Benefit

• Postmenopausal women with a BMI at or above 30, or BMI at or above 27 with at least one weight-related comorbidity (established cardiovascular disease, type 2 diabetes, hypertension, obstructive sleep apnea)
• Women with established cardiovascular disease who have not achieved adequate risk reduction through lifestyle modification alone, given the SELECT trial's cardiovascular mortality benefit
• Women who are mobile, willing to do resistance training, and able to maintain adequate protein intake
• Women with PCOS who remain symptomatic into their postmenopausal years: insulin resistance and androgen excess can persist after menopause, and Wegovy addresses the metabolic substrate

Women Who Should Proceed with Greater Caution

• Women with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2: Wegovy carries a black box warning for this risk
• Women with severe gastroparesis or a history of pancreatitis
• Women with active eating disorder history: appetite suppression in a woman with a history of restriction may worsen restrictive patterns
• Women who are already underweight for their height or who have significant sarcopenia at baseline: the muscle-loss risk may outweigh the benefit, and a geriatric assessment should precede a prescribing decision
• Women on multiple antihypertensives with poorly controlled blood pressure: orthostatic hypotension risk is high, and medication adjustment needs to precede or accompany titration

The Frailty Consideration

Frailty is a clinical syndrome defined by weight loss, exhaustion, low physical activity, slow walking speed, and low grip strength. At least three of the five criteria define frailty by the Fried phenotype, as described in research published in the Journal of Gerontology. Wegovy should generally not be used in women who are already frail. The weight loss it produces may accelerate functional decline in this population. Pre-frail women (one or two criteria) may still benefit but require intensive monitoring and structured exercise support from the start.

What the Evidence Gap Looks Like for Older Women

Women over 65 have been systematically underrepresented in GLP-1 trials. The STEP trials enrolled participants up to age 75, but the mean age in STEP 1 was approximately 46 years. Subgroup analyses for older adults exist but are underpowered to detect age-specific safety signals reliably. The SELECT trial had a higher mean age and a more relevant population for cardiovascular risk, but it was not designed to assess functional outcomes like gait speed, grip strength, or activities of daily living.

This is an honest limitation. What we know about muscle preservation, fall prevention, and functional independence with GLP-1 therapy in women over 65 is largely extrapolated from general geriatric medicine evidence and smaller mechanistic studies, not from dedicated large trials in this demographic. WomanRx's position, consistent with Obesity Society guidance, is that the drug can be used in older women with appropriate safeguards, but the exercise and protein prescription is not negotiable, and the frailty screen should happen before the prescription is written.

As one framework: think of Wegovy in a woman over 65 as a drug that requires an activity co-prescription to be safe and effective, not just advisable.